Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates
Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance
Cerecor's Crohn's Disease Candidate Shows Encouraging Response In Pretreated Patients
Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets
Top Penny Stocks to Buy Moving in Premarket? Check These 3 Out
Cerecor Shares Gain After FDA Fast Track Review Tag For CERC-002 In Hospitalized COVID-19 Patients
Cerecor's investigational COVID-19 therapy gets Fast Track designation from the FDA
A Small Biotech Stock That Has All The Right Ingredients for a Big 2021 Breakout
Cerecor Inks New Global License Agreement With Kyowa Kirin For CERC-002
Cerecor Reports 2020 Financial Results and Provides Business Updates
Cerecor to Present at Upcoming Investor Conferences
CERC Stock Price Increases Over 10% Pre-Market: Why It Happened
Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II
Cerecor Announces Proceeds from Option to Purchase Additional Shares of Common Stock Bringing Public Offering Proceeds to $40.7 Million
Cerecor Inc. Announces Closing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants
Cerecor Inc. Announces Pricing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants
Cerecor Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still's Disease
Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refractory Multiple Myeloma
Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-803 to Treat Leukocyte Adhesion Deficiency Type II
Cerecor to Collaborate with Frontiers CDG Consortium on Pivotal Trial of CERC-801 for the Treatment of PGM1-CDG
Cerecor Reports Third Quarter 2020 Financial Results and Provides Business Update
4 Health Stocks Stonepine Capital Loves (1 Has Gained 233% Since September 29)
Wither independent electricity regulation?
12 Healthcare Stocks Moving In Tuesday's After-Market Session
Jane Street Group LLC Buys New Stake in Cerecor Inc (NASDAQ:CERC)
What is a power market coupler and does India really need it?
Cerecor (CERC) Presents At Wedbush Pacgrow Healthcare Virtual Conference - Slideshow
Sage Therapeutics Announces Second Quarter 2020 Financial Results and Highlights Pipeline and Business Progress
Enable Midstream Announces Second Quarter 2020 Financial and Operating Results
PTC India gets nod to set up third power exchange; launch likely by next FY
With no place to call home, popular Jersey City soccer program at risk of shutting down after 18 years
Appellate Tribunal for Electricity defers renewable energy certificate trading by four weeks
APTEL postpones trading of renewable energy certificates till Aug 26
Global Hypotension Pipeline Monitor 2020 - Featuring BCO Pharma, Cerecor, La Jolla Pharma Company, Sintetica, Theravance Biopharma, and TrioxBio - ResearchAndMarkets.com
Column on school reopening was insightful; Don’t let greedy developers hijack our city; Allow soccer center to open | Letters
Here’s how stress in early life leads to depression in adolescence
Me ya sa Burtaniya ke sayar wa Saudiyya makamai? - BBC News Hausa
World Bank approves $15.2million to support Uganda’s COVID-19 response | Health
Tata Power's Mundra plant in final talks to ink supplemental PPA deal
Brokerages Expect Cerecor Inc (NASDAQ:CERC) Will Announce Quarterly Sales of $2.25 Million
Early life stress increases risk of developing depression in adulthood; Study
Early life stress is associated with youth-onset depression for some types of stress | Health
Acute Respiratory Distress Syndrome (ARDS) - Market Insights, Epidemiology and Forecast to 2030 - ResearchAndMarkets.com
Treatment-resistant depression (TRD) Market Trends & Epidemiology Forecasts to 2030 - Cariprazine (Allergan/Gedeon Richter) Expected to be Launched in the US Market by 2022 - ResearchAndMarkets.com
Setback for Tata, Adani, Essar: Gujarat scraps order to pay more for power
3 “Perfect 10” Healthcare Stocks That Have Plenty Of Growth On Tap
Acadia Pharmaceuticals: Evaluating The Upcoming Opportunities (NASDAQ:ACAD)
LivaNova Announces Publication Detailing the Design of the RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression